Literature DB >> 2510167

Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced by gene targeting.

H P Fell1, S Yarnold, I Hellström, K E Hellström, K R Folger.   

Abstract

We demonstrate that murine myeloma cells can efficiently mediate homologous recombination. The murine myeloma cell line J558L was shown to appropriately recombine two transfected DNA molecules in approximately 30% of cells that received and integrated intact copies of both molecules. This activity was then exploited to direct major reconstructions of an endogenous locus within a hybridoma cell line. Production of antigen-specific chimeric heavy chain was achieved by targeting the human IgG1 heavy chain constant region (C gamma 1) exons to the genomic heavy chain locus of a hybridoma cell line secreting antibody specific for a human tumor-associated antigen. The frequency of productive genomic recombinations was approximately 1 in 200 transfectants, with accumulation of the chimeric protein reaching greater than 20 micrograms/ml in culture supernatants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510167      PMCID: PMC298311          DOI: 10.1073/pnas.86.21.8507

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells.

Authors:  K R Thomas; M R Capecchi
Journal:  Cell       Date:  1987-11-06       Impact factor: 41.582

2.  High frequency targeting of genes to specific sites in the mammalian genome.

Authors:  K R Thomas; K R Folger; M R Capecchi
Journal:  Cell       Date:  1986-02-14       Impact factor: 41.582

3.  A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen.

Authors:  B G Sahagan; H Dorai; J Saltzgaber-Muller; F Toneguzzo; C A Guindon; S P Lilly; K W McDonald; D V Morrissey; B A Stone; G L Davis
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

4.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

5.  Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A.

Authors:  L K Sun; P Curtis; E Rakowicz-Szulczynska; J Ghrayeb; N Chang; S L Morrison; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

6.  Powerful and versatile enhancer-promoter unit for mammalian expression vectors.

Authors:  M K Foecking; H Hofstetter
Journal:  Gene       Date:  1986       Impact factor: 3.688

7.  Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.

Authors:  A Y Liu; R R Robinson; K E Hellström; E D Murray; C P Chang; I Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Monoclonal mouse antibodies raised against human lung carcinoma.

Authors:  I Hellström; D Horn; P Linsley; J P Brown; V Brankovan; K E Hellström
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

9.  Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.

Authors:  C Bode; M S Runge; E E Branscomb; J B Newell; G R Matsueda; E Haber
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

10.  Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.

Authors:  Y Nishimura; M Yokoyama; K Araki; R Ueda; A Kudo; T Watanabe
Journal:  Cancer Res       Date:  1987-02-15       Impact factor: 12.701

View more
  14 in total

1.  The molecular basis of multiple vector insertion by gene targeting in mammalian cells.

Authors:  P Ng; M D Baker
Journal:  Genetics       Date:  1999-03       Impact factor: 4.562

2.  Targeted inactivation of the insulin receptor gene in mouse 3T3-L1 fibroblasts via homologous recombination.

Authors:  D Accili; S I Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

3.  High-fidelity gene targeting in embryonic stem cells by using sequence replacement vectors.

Authors:  K R Thomas; C Deng; M R Capecchi
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

4.  Gene replacement with one-sided homologous recombination.

Authors:  N Berinstein; N Pennell; C A Ottaway; M J Shulman
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

5.  Detection of gene targeting by co-conversion of a single nucleotide change during replacement recombination at the immunoglobulin mu heavy chain locus.

Authors:  A J Smith; B Kalogerakis
Journal:  Nucleic Acids Res       Date:  1991-12       Impact factor: 16.971

Review 6.  Prospects for homologous recombination in human gene therapy.

Authors:  M A Vega
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

7.  Production of recombinant granulocyte colony-stimulating factor by knocking into the active immunoglobulin heavy chain gene locus in the hybridoma cell line.

Authors:  Y Kuwana; K Funayama; H Miyaji; M Hasegawa; H Yoshida; S Itoh
Journal:  Cytotechnology       Date:  2001-11       Impact factor: 2.058

8.  Genetic stability of gene targeted immunoglobulin loci. I. Heavy chain isotype exchange induced by a universal gene replacement vector.

Authors:  C Kardinal; M Selmayr; R Mocikat
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

9.  Investigation of coelectroporation as a method for introducing small mutations into embryonic stem cells.

Authors:  A C Davis; M Wims; A Bradley
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

10.  An internal ribosome binding site can be used to select for homologous recombinants at an immunoglobulin heavy-chain locus.

Authors:  C R Wood; G E Morris; E M Alderman; L Fouser; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.